Compare General Motors Company (GM) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Summit Therapeutics Inc — how do they compare? General Motors Company trades at $82.74 (market cap $72.17B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: General Motors Company is far larger — about 5.3× Summit Therapeutics Inc's market cap, and General Motors Company pays a 0.88% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Summit Therapeutics Inc for 16 Days on average.
| GM | SMMT | |
|---|---|---|
Market Cap | $72.17B | $13.71B |
Volume | 4,900,304 | 6,173,057 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $26.38 |
52-Week Low | $55.35 | $12.43 |
Typical Hold Time | 83 Days | 16 Days |
Enterprise Value | $175.15B | $13.04B |
Dividend Yield | 0.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $82.73, up 2.15% with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong operating cash flow of $26.87B in 2025 but declining profit margins. Recent Q3 2026 sales fell 5.5% as EV demand weakens and Toyota challenges GM's U.S. sales leadership. Analyst consensus remains bullish with a $102.08 price target, though technical indicators show resistance at $83-$85 levels.
GM faces near-term headwinds from declining vehicle sales and margin pressure, but cost savings from eased fuel economy rules ($20.4B through 2031) and strong cash generation provide stability. The stock trades at attractive valuations (P/S 0.42) with 67% analyst buy ratings, though competitive threats and EV transition challenges require monitoring for sustained recovery.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
